A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

NCT03882970 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication tirzepatide compared to insulin degludec in adults with type 2 diabetes to see how it affects their blood sugar levels over time.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 1,444 people

Who can join Ages 18+ · all sexes

Timeline Started 2019-04 · est. completion 2021-01

Where 122 sites · Argentina, Austria, Greece, Hungary, Italy, Poland, Puerto Rico, Romania, South Korea, Spain, Taiwan, Ukraine, United States

What this study is testing ClinicalTrials.gov NCT03882970 ↗

Description as written by the study sponsor.

The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes. The study will last about 67 weeks and may include up to 22 visits.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Insulin Degludec Drug

Administered SC

Main thing measured	Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03882970 ↗